Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Appian Corp (APPN) vs Incyte Corporation (INCY) Price & Performance

Appian CorpTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Appian Corp vs Incyte Corporation — how do they compare? Appian Corp trades at $35.5 (market cap $2.54B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 9.7× Appian Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.

APPNINCY
Market Cap
$2.54B$24.54B
Sector
TechnologyHealth
52-Week High
$45.64$129.93
52-Week Low
$18.72$81.61
Enterprise Value
$2.67B$20.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Appian Corp

Appian (APPN) trades at $34.82, down 2.14% on the day despite strong technical momentum. The stock shows bullish moving average signals but overbought RSI readings. Fundamentally, the company delivered three consecutive earnings beats with Q2 2026 EPS of $0.13 beating expectations of $0.00308, while revenue grew 19% year-over-year to $203.3 million. Recent news highlights AI-powered underwriting partnerships and strong enterprise demand driving growth.

Appian presents a mixed investment case with strong revenue growth and AI momentum offset by negative profitability metrics and elevated valuations. The stock trades above analyst consensus target of $32.50, suggesting limited near-term upside. Key risks include persistent negative ROE (-936.62%) and high debt levels, though improving cash flow and AI adoption provide growth catalysts.

Incyte Corporation

Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.

The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.

Returns comparison

Trailing returns across standard periods

About Appian Corp

Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.

Read more on APPN

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY